loader from loading.io
Hypothalamic Gatekeepers, Tau Clearance, Neurodegeneration 🔍 show art Hypothalamic Gatekeepers, Tau Clearance, Neurodegeneration 🔍

Dr. RR Baliga's 'Podkast for the Kurious Doc'

A fascinating new study reveals a previously underappreciated pathway for tau clearance in the brain.   Researchers show that tanycytes—specialized hypothalamic glial cells—actively transport tau from cerebrospinal fluid into the bloodstream. In Alzheimer disease, these cells become fragmented and dysfunctional, impairing tau clearance and potentially accelerating neurodegeneration.   This work opens an intriguing avenue: could restoring tanycyte function enhance tau removal and slow Alzheimer progression?   A small cellular gatekeeper may hold an important clue in the...

info_outline
Obesity, Immunity, Cancer 🛡️🧬⚖️ The Metabolic Battlefield show art Obesity, Immunity, Cancer 🛡️🧬⚖️ The Metabolic Battlefield

Dr. RR Baliga's 'Podkast for the Kurious Doc'

Obesity is not simply excess weight—it is a metabolic and inflammatory state that can reshape cancer biology. Adipose tissue alters hormones, insulin signaling, inflammatory cytokines, and immune responses, creating conditions that favor tumor development. Evidence now links obesity with cancers of the breast, colon, endometrium, pancreas, liver, kidney, and esophagus. Understanding these mechanisms opens the door to precision prevention strategies, from weight management to metabolic therapies. The message from translational science is clear: metabolism and malignancy are deeply...

info_outline
🧬 Apolipoprotein M and Vascular Health: Carrier. Communicator. Controller. show art 🧬 Apolipoprotein M and Vascular Health: Carrier. Communicator. Controller.

Dr. RR Baliga's 'Podkast for the Kurious Doc'

🧬 Apolipoprotein M (ApoM) is emerging as a key regulator of vascular biology.   ApoM, an HDL-associated lipocalin, transports sphingosine-1-phosphate (S1P) and selectively activates S1PR1 signaling in endothelial cells.   This pathway stabilizes the endothelial barrier, promotes nitric-oxide mediated vasodilation, and suppresses vascular inflammation.   Clinical studies increasingly link lower ApoM levels with cardiometabolic disease, CKD, and heart failure risk.   New therapies—including ApoM-fusion biologics and selective S1PR1 agonists—may harness this pathway for...

info_outline
Dr RR Baliga's Philosophical Discourses: Simone de Beauvoir (France, 1908–1986 CE) – Feminist Philosophy show art Dr RR Baliga's Philosophical Discourses: Simone de Beauvoir (France, 1908–1986 CE) – Feminist Philosophy

Dr. RR Baliga's 'Podkast for the Kurious Doc'

📚 Simone de Beauvoir (1908–1986) — philosopher, writer, and architect of modern feminism.   Her groundbreaking book The Second Sex (1949) reshaped global conversations on gender with one powerful line: “One is not born, but becomes, a woman.”   She challenged stereotypes, defended women’s autonomy, and influenced second-wave feminism worldwide.   Her ideas still echo in medicine, education, ethics, and leadership today.   Freedom. Responsibility. Equality. 💡✊📖 

info_outline
Pulmonary Embolism ACC/AHA 2026 guidelines: Precision Over Panic show art Pulmonary Embolism ACC/AHA 2026 guidelines: Precision Over Panic

Dr. RR Baliga's 'Podkast for the Kurious Doc'

🫁 Pulmonary Embolism in 2026 — A Precision Framework The new AHA/ACC Acute Pulmonary Embolism Guideline redefines how we classify and treat PE. Key updates: • Category A–E clinical classification integrating hemodynamics, biomarkers, and RV imaging • Age-adjusted D-dimer and YEARS algorithm to reduce unnecessary imaging • CT pulmonary angiography as preferred diagnostic modality • RV/LV ratio reporting for objective risk stratification • LMWH → DOAC preferred for anticoagulation • Advanced therapies for cardiopulmonary failure • Mandatory 1-year follow-up to screen for...

info_outline
🧬⏰ Can We Slow Immune Aging? Science Says Maybe show art 🧬⏰ Can We Slow Immune Aging? Science Says Maybe

Dr. RR Baliga's 'Podkast for the Kurious Doc'

🧬✨ Can we make the ageing immune system young again?   A fascinating Nature study shows that a three-part mRNA cocktail (DFI) can temporarily rejuvenate T cells in aged mice, improving responses to vaccines and cancer immunotherapy—without breaking immune tolerance. By turning the liver into a short-term factory for key immune signals (DLL1, FLT3L, IL-7), the authors demonstrate that immune ageing is modifiable, not fixed.   This elegant work—covered by Heidi Ledford in —opens provocative questions about immune resilience, ageing biology, and the future of mRNA beyond...

info_outline
🫀 Lancet Seminar: Atrial Fibrillation — Detect. Protect. Correct. show art 🫀 Lancet Seminar: Atrial Fibrillation — Detect. Protect. Correct.

Dr. RR Baliga's 'Podkast for the Kurious Doc'

Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting ~37.6 million people globally, with prevalence expected to double in the coming decades.    A recent Lancet Seminar (2026) highlights several key principles shaping modern AF care:   • Stroke prevention with oral anticoagulation remains the cornerstone • Early rhythm control strategies improve cardiovascular outcomes • Catheter ablation is increasingly used as first-line therapy • Lifestyle modification—weight loss, exercise, alcohol reduction—reduces AF burden • Integrated care models...

info_outline
🧬 Protein Restriction, Aging, and Longevity ⏳ show art 🧬 Protein Restriction, Aging, and Longevity ⏳

Dr. RR Baliga's 'Podkast for the Kurious Doc'

🧬 Protein Restriction, Aging, and Longevity ⏳   A remarkable new study in Cell shows that moderate protein restriction—especially when started in midlife—can reprogram aging biology across 41 organs, improving metabolic and cardiovascular health. 🫀⚙️   Using deep multi-organ proteomics in mice and human plasma validation, the authors demonstrate benefits mediated through ↓ IGF-1, ↓ mTOR, ↑ AMPK, and activation of brown adipose tissue. Importantly, the data also caution that extreme protein restriction may provoke inflammation, underscoring that moderation...

info_outline
Resistant Hypertension. Target Aldosterone. Transform Care 🚀 show art Resistant Hypertension. Target Aldosterone. Transform Care 🚀

Dr. RR Baliga's 'Podkast for the Kurious Doc'

Resistant hypertension remains one of the most stubborn challenges in cardiovascular medicine.   The Bax24 phase 3 trial, published in The Lancet (2026), evaluated baxdrostat, a selective aldosterone synthase inhibitor, in patients already receiving multiple antihypertensive agents.   Key findings: • −16.6 mmHg reduction in 24-hour ambulatory SBP • −14.0 mmHg placebo-corrected difference (p<0.0001) • 71% achieved BP control (<130 mmHg) vs 17% placebo • Acceptable safety profile, with hyperkalemia in 3%   These data highlight the growing importance of...

info_outline
Exercise Types, Variety, Vitality 🌈🚴‍♀️🫀 show art Exercise Types, Variety, Vitality 🌈🚴‍♀️🫀

Dr. RR Baliga's 'Podkast for the Kurious Doc'

🏃‍♀️🏋️‍♂️ Does variety in physical activity matter for longevity? A large prospective analysis suggests it does: people who engaged in a wider mix of activity types tended to have lower all-cause mortality, even after accounting for total activity and key covariates. 🌈📉   Key practical takeaway: don’t just “do more”—do different (walk + cycle + swim + strength, etc.). ✅🫀   As always, this is observational data (residual confounding + self-report remain). Still, it’s a compelling nudge toward diversity in movement as a realistic,...

info_outline
 
More Episodes

Coronary CT angiography-guided management of patients
with stable chest pain: 10-year outcomes from the SCOT-
HEART randomised controlled trial in Scotland


Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators*


Summary
Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management
guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in
management and outcomes.


Methods SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from
12 outpatient cardiology chest pain clinics across Scotland. Eligible patients were aged 18–75 years with symptoms of
suspected stable angina due to coronary heart disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis, prescribing data, coronary procedural
interventions, and clinical outcomes were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial infarction on an intention-to-treat basis. This trial
is registered at ClinicalTrials.gov (NCT01149590) and is complete.


Findings Between Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57 years [SD 10], 2325 [56·1%] male, 1821 [43·9%] female), with 2073 randomly assigned to standard care and CCTA and 2073 to standard care
alone. After a median of 10·0 years (IQR 9·3–11·0), coronary heart disease death or non-fatal myocardial infarction
was less frequent in the CCTA group compared with the standard care group (137 [6·6%] vs 171 [8·2%]; hazard ratio
[HR] 0·79 [95% CI 0·63–0·99], p=0·044). Rates of all-cause, cardiovascular, and coronary heart disease death, and
non-fatal stroke, were similar between the groups (p>0·05 for all), but non-fatal myocardial infarctions (90 [4·3%] vs
124 [6·0%]; HR 0·72 [0·55–0·94], p=0·017) and major adverse cardiovascular events (172 [8·3%] vs 214 [10·3%];
HR 0·80 [0·65–0·97], p=0·026) were less frequent in the CCTA group. Rates of coronary revascularisation procedures
were similar (315 [15·2%] vs 318 [15·3%]; HR 1·00 [0·86–1·17], p=0·99) but preventive therapy prescribing remained
more frequent in the CCTA group (831 [55·9%] of 1486 vs 728 [49·0%] of 1485 patients with available data; odds ratio
1·17 [95% CI 1·01–1·36], p=0·034).


Interpretation After 10 years, CCTA-guided management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal myocardial infarction. Identification of coronary
atherosclerosis by CCTA improves long-term cardiovascular disease prevention in patients with stable chest pain.